当前位置:首页 / 降压药物阶梯下调模式在经沙库巴曲缬沙坦治疗后LVEF改善的HFrEF患者中的可行性、安全性及对心功能的影响:一项随机对照试验
| 更新时间:2026-11-20
|
降压药物阶梯下调模式在经沙库巴曲缬沙坦治疗后LVEF改善的HFrEF患者中的可行性、安全性及对心功能的影响:一项随机对照试验
Feasibility and safety of a step-down de-escalation strategy for antihypertensive medications and its effect on cardiac function in heart failure with reduced ejection fraction patients with improved left ventricular ejection fraction after sacubitril/valsartan therapy: a randomized controlled trial

内科 页码:551-557

作者机构:信阳市中心医院 1 心血管内科,2 全科医学科,河南省信阳市 464000

DOI:10.16121/j.cnki.cn45-1347/r.2026.05.07

  • 中文简介
  • 英文简介
  • 参考文献

目的 探讨降压药物阶梯下调模式在经沙库巴曲缬沙坦治疗后左心室射血分数(LVEF)改善的射血分数降低的心力衰竭(HFrEF)患者中的可行性、安全性及其对心功能的影响。方法 选取2024年1月至2025年3月信阳市中心医院心血管内科收治的经沙库巴曲缬沙坦治疗后LVEF改善(≥45%)的HFrEF患者120例,采用随机数字表法将其分为阶梯下调组(60例)和常规治疗组(60例)。两组全程(共24周)维持沙库巴曲缬沙坦目标剂量或最大耐受剂量并接受标准基础治疗;同时,阶梯下调组按照预设阶梯下调方案逐步减少降压药物的使用种类与剂量,常规治疗组维持原方案且不主动减药。比较两组的主要观察指标[因心力衰竭再住院、全因死亡、主要不良心血管事件(MACE)及不良反应的发生情况]及次要观察指标[血压、LVEF、左心室舒张末期内径(LVEDD)、N末端B型利钠肽原(NT-proBNP)水平及降压药物使用种类和剂量]。结果 阶梯下调组低血压发生率为5.00%(3/60),低于常规治疗组的16.67%(10/60)(P<0.05);两组因心力衰竭再住院率、全因死亡率及MACE、高钾血症、肾功能恶化发生率差异均无统计学意义(均P>0.05)。两组基线及入组24周后的收缩压、舒张压、LVEF、LVEDD及NT-proBNP水平差异均无统计学意义(均P>0.05);与基线比较,阶梯下调组入组24周后LVEF升高,两组LVEDD及NT-proBNP水平均降低(均P<0.05)。入组24周后,阶梯下调组降压药物使用种类及限定日剂量均少于常规治疗组(均P<0.05)。结论 对于经沙库巴曲缬沙坦治疗后LVEF改善的HFrEF患者,在沙库巴曲缬沙坦全程维持和严密监测的前提下实施降压药物阶梯下调模式,既未增加MACE风险,亦未恶化心功能或影响血压控制,又减少降压药物的使用种类与剂量,降低低血压发生风险。

Objective To evaluate the feasibility and safety of a step-down de-escalation strategy for antihypertensive medications and its effect on cardiac function in patients with heart failure with reduced ejection fraction (HFrEF) who achieved improved left ventricular ejection fraction (LVEF) after sacubitril/valsartan therapy.Methods A total of 120 HFrEF patients with improved LVEF (≥45%) after sacubitril/valsartan therapy, admitted to the Department of Cardiovascular Medicine of Xinyang Central Hospital from January 2024 to March 2025, were enrolled. Using a random number table, patients were assigned to a step-down group (n=60) and a conventional treatment group (n=60). Throughout the 24-week study period, both groups maintained sacubitril/valsartan at the target dose or maximum tolerated dose and received standard foundational therapy. Meanwhile, the step-down group underwent gradual reduction in the number and dosage of antihypertensive agents according to a prespecified step-down protocol, whereas the conventional treatment group continued their original regimen without active de-escalation. The primary outcomes (heart failure rehospitalization, all-cause mortality, major adverse cardiovascular events [MACE], and adverse reactions) and secondary outcomes (blood pressure, LVEF, left ventricular end-diastolic diameter [LVEDD], N-terminal pro-B-type natriuretic peptide [NT-proBNP] levels, and the number and dosage of antihypertensive agents) were compared between the two groups. Results The incidence of hypotension was 5.00% (3/60) in the step-down group, lower than 16.67% (10/60) in the conventional treatment group (P<0.05). No significant between-group differences were observed in heart failure rehospitalization, all-cause mortality, MACE, hyperkalemia, or worsening renal function (all P>0.05). No significant between-group differences were found in systolic blood pressure, diastolic blood pressure, LVEF, LVEDD, or NT-proBNP levels at baseline or at 24 weeks (all P>0.05). Compared with baseline, LVEF increased in the step-down group at 24 weeks, and LVEDD and NT-proBNP levels decreased in both groups (all P<0.05). At 24 weeks, the step-down group used fewer antihypertensive agents and had a lower defined daily dose than the conventional treatment group (both P<0.05). Conclusion Under continuous sacubitril/valsartan maintenance and close monitoring, a step-down de-escalation strategy for antihypertensive medications reduces the number and dosage of antihypertensive agents and lowers the risk of hypotension in HFrEF patients with improved LVEF after sacubitril/valsartan therapy, without increasing MACE risk, deteriorating cardiac function, or compromising blood pressure control. 


    无

5

浏览量

0

下载量

0

CSCD

工具集